A5023045485- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Head and Neck Cancer Studies
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Radiopharmaceutical Chemistry and Applications
- Cancer Diagnosis and Treatment
- Cervical Cancer and HPV Research
- Nutrition and Health in Aging
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Hypoxia, and Metabolism
- Cancer Treatment and Pharmacology
- Metastasis and carcinoma case studies
- Head and Neck Surgical Oncology
- Enhanced Recovery After Surgery
- Pelvic floor disorders treatments
- Lung Cancer Treatments and Mutations
- Salivary Gland Tumors Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Economic and Financial Impacts of Cancer
- Bone health and treatments
- Renal and related cancers
- Colorectal and Anal Carcinomas
Deleted Institution
2009-2024
Institute of Research and Innovation Parc Tauli
2017-2023
Corporació Sanitària Parc Taulí
2010-2023
Universitat Autònoma de Barcelona
2018-2023
Complejo Hospitalario de Cáceres
2022
Massachusetts General Hospital
2015
Boston University
2015
Uppsala University Hospital
2015
Centro Infantil Boldrini
2015
Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, response to treatment. Radiation therapy an essential component curative-intent non-disseminated disease association chemotherapy improves rates survival. In case metastatic stages, treatment requires platinum/gemcitabine-based patients may achieve a long survival time.
Background: Anti-epithermal-growth-factor-receptor (EGFR) therapies in combination with radiotherapy are being studied on de-escalation clinical trials for HPV-related oropharyngeal cancer (OPC) patients. The HPV16-E5 oncoprotein increases recycling of activated EGFR to the cell surface, enhancing factor signal transduction. Our aim was evaluate viral oncogene expression as well and phosphorylated-EGFR (pEGFR), protein levels biomarkers outcome a retrospective cohort OPC Methods:...
Durvalumab, a human immunoglobulin G1 kappa monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with PD-1 and CD80 (B7.1) molecules, is increasingly used in advanced neoplasias. Durvalumab use associated increased immune-related adverse events. We report case 55-year-old man who presented to our emergency room hyperglycaemia after receiving durvalumab for urothelial high-grade non-muscle-invasive bladder cancer. On presentation, he had polyuria,...
The incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing in some regions. Nevertheless, the epidemiology this disease has not been extensively investigated southern Europe. We conducted a retrospective cohort study patients diagnosed with primary from 1991 to 2016. Cancer tissues underwent histopathological evaluation, DNA quality control, HPV-DNA detection and p16INK4a immunohistochemistry. Data were collected medical records. Factors associated HPV positivity...
15 Background: Docetaxel improves survival in patients (pts) with metastatic hormonosensitive prostate cancer (PC) and castration-resistant cancer. The objective of this phase IIb trial was to assess the activity low dose docetaxel concurrent radiotherapy plus standard hormonal treatment pts high risk localized CaP. Methods: High-risk CaP defined by ≥ 1 following criteria: T3-T4, Gleason score (GS) 8, PSA > 20 ng/mL, pN+. Pts were randomly assigned either arm A (LH-RH analogs every 3...
Background Given the different nature and better outcomes of oropharyngeal carcinoma (OPC) associated with human papillomavirus (HPV) infection, a novel clinical stage classification for HPV-related OPC has been accepted 8th edition AJCC TNM (ICON-S model). However, it is still unclear HPV-relatedness definition best diagnostic accuracy prognostic value. Material methods The aim this study was to compare staging system models proposed patients: 7th TNM, RPA non-anatomic factors (Princess...
Abstract Background. The combination of gemcitabine plus capecitabine and sunitinib (GCS) shows activity in metastatic renal cell carcinoma (mRCC). We tested the multitargeted “chemo-switch” regimen as first-line treatment patients with mRCC. Methods. assessed maximum tolerated dose antitumor GCS treatment-naïve, advanced mRCC patients. Treatment consisted intravenous on days 1 8, oral twice daily 1–14, for six 21-day cycles, followed by monotherapy at investigator's discretion. Dose level 0...
TPS4591 Background: Cisplatin-based chemotherapy is standard first line treatment for metastatic urothelial carcinoma (mUC). However, around 50% of patients are ineligible cisplatin due to poor performance status or comorbidities. For these cases, carboplatin-based combinations valid alternative options, although they associated with inferior survival. Additional new strategies cisplatin-ineligible therefore urgently needed. Recently, excellent clinical activity has been reported immune...
e15095 Background: Gemcitabine (G) plus Capecitabine (C) have demonstrated a modest activity in metastatic renal cell cancer (mRCC) patients (pts). The combination of Sunitinib (S) and C resulted an acceptable safety profile pts with advanced solid tumors. We hypothesized that the addition S to G+C advanced/mRCC would be synergistic could increase therapeutic efficacy. Methods: This is open-label, phase I, dose-escalation study assess maximum-tolerated dose (MTD), antitumor (in terms...